Estados Unidos · Bolsa y Finanzas · MarketWatch

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Publicado por MarketWatch · Estados Unidos hace 9 h

Alector entered into an exclusive global licensing agreement with Genetech, which will receive worldwide rights to develop and commercialize Alector's AL050 program.

Leer el artículo completo en MarketWatch Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketwatch.com)

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

También te puede interesar

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Half of bond ETFs now show negative one-year returns

My partner and I always thought we agreed on money. Then, we moved in together.

Metaplanet reveals net income strategy to fuel Bitcoin accumulation

Stripe to expand stablecoin cards to over 100 countries by the end of the year

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Compartir

También te puede interesar

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Half of bond ETFs now show negative one-year returns

My partner and I always thought we agreed on money. Then, we moved in together.

Metaplanet reveals net income strategy to fuel Bitcoin accumulation

Stripe to expand stablecoin cards to over 100 countries by the end of the year